Drug Detail

Information about

Generic Name
IND
Brand Name (US)
Manufacturer	CStone Pharmaceuticals
Drug Type	Trial Combination
Delivery	Intravenous + Oral
Approval Status	CS1001 is in Phase 3, Regorafenib is approved for GIST
Indications
Overall Strategy	tumor signal path + immune system
Strategy	Immune checkpoint inhibitor enhanced by TKI
Drug Category	PD-L1 inhibitor + TKI

Links
	CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib

Trials of this drug
	A Study of CS1001 in Subjects With Advanced or Refractory Solid Tumors

Trial results